Tradestie Institutional Equity Comparison Engine

RDY vs TAK โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

TAK Overall Edge

TAK Captures Institutional Edge (4โ€“0 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, RDY trades at 31.6x Forward P/E with 9.1% operating margin (-1.5% YoY revenue) versus TAK at 12.7x Forward P/E and 16.6% operating margin (+6.7% YoY). In options structure, RDY sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against TAK sits in UNCLASSIFIED (5th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner TAK
RDY 31.6x vs TAK 12.7x Fwd P/E
Growth & Margin Winner TAK
Op Margin 9.1% vs 16.6% ยท YoY -1.5% vs +6.7%
Momentum & Technical Winner TAK
1Y +5.9% vs +51.8% ยท 52W Pos 77% vs 97%
Options & Structure Winner TAK
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (5th %ile IV)
RDY NYSE
Dr. Reddy's Laboratories Limited American Depositary Shares
Pharmaceutical Preparations
$14.69
-0.34% 1D
Market Cap $12.3B
1M Return +12.39%
1Y Return +5.91%
Forward P/E 31.6x
Unified AI Score
34.7 / 100 SELL
Tech 17.0 Fund 34.0 Flow 50.0 Mom 40.0
TAK NYSE
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
1M Return +9.89%
1Y Return +51.79%
Forward P/E 12.7x
Unified AI Score
48.0 / 100 HOLD
Tech 43.0 Fund 44.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RDY +5.91% TAK +51.79% Spread: +45.88 pp (TAK Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
RDY TTM Op. Margin: 9.1% TAK TTM Op. Margin: 16.6%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RDY vs TAK. Trailing 12-month operating profitability (RDY 9.1% vs TAK 16.6%) and valuation multiples (RDY 31.6x vs TAK 12.7x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RDY (3) vs TAK (7)
Institutional Metric RDY TAK Criterion Row Winner
Market Capitalization Scale $12.3B $67.5B Larger Scale TAK
Trailing P/E Ratio Valuation 41.0x N/M Lower Multiple RDY
Forward P/E Ratio Valuation 31.6x 12.7x Lower Multiple TAK
Revenue Growth (YoY) Growth -1.5% +6.7% Higher Growth TAK
Operating Margin (TTM) Profitability 9.1% 16.6% Higher Margin TAK
Net Profit Margin Profitability 8.5% 0.9% Higher Margin RDY
Return on Equity (ROE) Capital Efficiency 7.3% 0.6% Higher ROE RDY
52-Week Range Position Momentum 77% ($11โ€“$16) 97% ($14โ€“$22) Stronger Trend TAK
Beta / 30D Volatility Risk Regime 0.39ฮฒ ยท 24% Vol -0.02ฮฒ ยท 22% Vol Lower Realized Risk TAK
Unified Institutional Score Composite Signal 34.7 / 100 (SELL) 48.0 / 100 (HOLD) Higher Composite TAK

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RDY vs TAK Buy Guide
RDY UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live RDY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
TAK UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live TAK Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RDY nor TAK registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.